IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation
NASDAQ:IDXX • US45168D1046
648.7 USD
+13.16 (+2.07%)
At close: Mar 4, 2026
648.7 USD
0 (0%)
After Hours: 3/4/2026, 8:00:03 PM
This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Overall IDXX gets a fundamental rating of 7 out of 10. We evaluated IDXX against 184 industry peers in the Health Care Equipment & Supplies industry. IDXX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IDXX has a decent growth rate and is not valued too expensively. These ratings would make IDXX suitable for quality investing!
1. IDXX Profitability Analysis
1.1 Basic Checks
- In the past year IDXX was profitable.
- In the past year IDXX had a positive cash flow from operations.
- IDXX had positive earnings in each of the past 5 years.
- Each year in the past 5 years IDXX had a positive operating cash flow.
1.2 Ratios
- IDXX's Return On Assets of 30.34% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
- Looking at the Return On Equity, with a value of 65.81%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 40.35%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- IDXX had an Average Return On Invested Capital over the past 3 years of 37.60%. This is significantly above the industry average of 8.90%.
- The last Return On Invested Capital (40.35%) for IDXX is above the 3 year average (37.60%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- IDXX has a Profit Margin of 24.65%. This is amongst the best in the industry. IDXX outperforms 95.11% of its industry peers.
- IDXX's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 31.34%, IDXX belongs to the top of the industry, outperforming 98.91% of the companies in the same industry.
- In the last couple of years the Operating Margin of IDXX has grown nicely.
- IDXX has a better Gross Margin (61.72%) than 64.67% of its industry peers.
- IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. IDXX Health Analysis
2.1 Basic Checks
- IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, IDXX has less shares outstanding
- The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
- IDXX has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 21.80 indicates that IDXX is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 21.80, IDXX belongs to the best of the industry, outperforming 96.20% of the companies in the same industry.
- The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
- IDXX's Debt to FCF ratio of 1.04 is amongst the best of the industry. IDXX outperforms 90.22% of its industry peers.
- A Debt/Equity ratio of 0.53 indicates that IDXX is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.53, IDXX is in line with its industry, outperforming 40.22% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.8 |
ROIC/WACC4.04
WACC9.99%
2.3 Liquidity
- A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
- IDXX has a Current ratio of 1.18. This is amonst the worse of the industry: IDXX underperforms 82.07% of its industry peers.
- A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
- With a Quick ratio value of 0.87, IDXX is not doing good in the industry: 82.07% of the companies in the same industry are doing better.
- IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. IDXX Growth Analysis
3.1 Past
- IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.18%, which is quite good.
- The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
- Looking at the last year, IDXX shows a quite strong growth in Revenue. The Revenue has grown by 10.42% in the last year.
- The Revenue has been growing by 9.72% on average over the past years. This is quite good.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.75% on average per year.
- IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. IDXX Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 49.63, the valuation of IDXX can be described as expensive.
- 69.57% of the companies in the same industry are more expensive than IDXX, based on the Price/Earnings ratio.
- IDXX is valuated expensively when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
- IDXX is valuated quite expensively with a Price/Forward Earnings ratio of 43.78.
- IDXX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 68.48% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 25.11. IDXX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.63 | ||
| Fwd PE | 43.78 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 67.39% of the companies listed in the same industry.
- 71.20% of the companies in the same industry are more expensive than IDXX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.09 | ||
| EV/EBITDA | 35.31 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
- IDXX's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.71
PEG (5Y)3.48
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. IDXX Dividend Analysis
5.1 Amount
- No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDXX Fundamentals: All Metrics, Ratios and Statistics
648.7
+13.16 (+2.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner Change11.43%
Ins Owners0.21%
Ins Owner Change2.2%
Market Cap51.80B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target768.59 (18.48%)
Short Float %2.2%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-1.91%
PT rev (3m)-0.59%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.06%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.63 | ||
| Fwd PE | 43.78 | ||
| P/S | 12.43 | ||
| P/FCF | 55.09 | ||
| P/OCF | 47.61 | ||
| P/B | 33.18 | ||
| P/tB | 50.16 | ||
| EV/EBITDA | 35.31 |
EPS(TTM)13.07
EY2.01%
EPS(NY)14.82
Fwd EY2.28%
FCF(TTM)11.77
FCFY1.82%
OCF(TTM)13.63
OCFY2.1%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.71
PEG (5Y)3.48
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.8 |
F-Score8
WACC9.99%
ROIC/WACC4.04
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.71%
EBIT Next 3Y14.82%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 49.63 and the Price/Book (PB) ratio is 33.18.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.